Sabre Insurance Group PLC (SBRE)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 169.00 |
|---|---|
| 52-week range | 123.00 – 188.80 |
| Return, 1 month / 3 months | −0.5% / −5.7% |
| Return, 1 year / 3 years | +37.0% / +43.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 44 |
| Volatility (1 year) | 25.2% |
| Worst drawdown (1 year) | -10.5% |
| Average daily value traded | 83.01M GBX |
| Dividend yield | 8.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sabre Insurance Group is a British motor insurer that underwrites private car policies, concentrating on specialist and non-standard risks such as drivers with convictions, younger drivers or those who struggle to find cover elsewhere. It distributes its policies through insurance brokers and price comparison websites rather than operating its own consumer brand, and it is based in the United Kingdom, where it writes the bulk of its business.
On this site Sabre Insurance Group PLC appears as a stock on the London Exchange (UK), code SBRE, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sabre Insurance Group PLC (SBRE) trades on the London Exchange in UK. It last closed at GBX 169.00 on 23 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 168 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 37.0% and over the last three months it fell 5.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 77 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 9.7% | ||
| From 52-week high | -9.5% | ||
| Momentum | 65 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -5.7% | ||
| 6-month return | 13.7% | ||
| 12-month return, skipping the last month | 37.7% | ||
| Stability (higher is calmer) | 85 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 25.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -10.5% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 83.01M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 67 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 8.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −8.4% |
|---|---|
| 1 month | −0.5% |
| 3 months | −5.7% |
| 6 months | +13.7% |
| 1 year | +37.0% |
| 3 years | +43.1% |
| 5 years | +21.0% |
Signals
| 50-day / 200-day average | 172.72 / 154.06 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.92 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Aug 2026 | GBP 0.0410 |
| 23 Apr 2026 | GBP 0.1010 |
| 21 Aug 2025 | GBP 0.0340 |
| 17 Apr 2025 | GBP 0.1130 |
| 22 Aug 2024 | GBP 0.0170 |
| 25 Apr 2024 | GBP 0.0810 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.